3 questions to learn if your baby's gut is healthy.
DAVIS, Calif., September 20, 2018 – Evolve BioSystems, makers of Evivo® baby probiotic, today unveiled its prototype for the first-ever point-of-care infant gut microbiome screening test. Using a small stool sample collected from a diaper, the test will detect levels of Bifidobacterium, a group of beneficial gut bacteria that are especially critical during infancy. The Evivo stool test will allow doctors to discern whether babies have high or low levels of this key beneficial bacteria, Bifidobacterium.
“This is the first and only point-of-care screening test designed to identify infants that do not have enough Bifidobacterium levels to create a stable infant gut microbiome,” said Dr. Bethany Henrick, PhD, Director of Immunology and Diagnostics for Evivo. “With recent research indicating most babies born after 1980 do not acquire Bifidobacterium at birth, our ability to detect significant levels of Bifidobacterium gives pediatricians and parents an immediate indication of whether or not their baby has this beneficial gut bacteria.
Watch a demo of the Evivo Stool Test
Read the press release
Davis, California, September 18, 2018 – Evolve BioSystems, Inc., announced new study results showing that breastfed babies colonized by Bifidobacterium longum subsp. infantis EVC001 (the probiotic bacteria found in Evivo® ) displayed significantly less evidence of mucin degradation compared to control infants who did not receive the beneficial Bifidobacterium. This is significant because the loss of mucin, a key component of the intestinal mucus layer, exposes the gut epithelium to potentially damaging interactions with the gut microbiome.
To read this article in full:
Davis, California, July 18, 2018 – Evolve BioSystems, Inc., announced it has published a study showing that two weeks of supplementation with Bifidobacterium longum subsp. infantis EVC001 (B. infantis EVC001, currently available to consumers as Evivo baby probiotic) in breastfed infants led to an 85 percent reduction in virulence factor genes, which enable pathogens to thrive and cause infection in humans. The paper, published in Human Microbiome Journal, is the first study to report a significant reduction of virulence factors in the infant gut bacterial community by way of a targeted probiotic supplementation. Among other findings, the study shows common pathogenic bacterial species being reduced by at least 93 percent.
“The neonatal population is particularly susceptible to microbial infections. Microbes that express virulence factors can establish persistent reservoirs in the hospital environment and colonize newborn infants,” said Brian Scottoline, M.D., Ph.D., associate professor of pediatrics (neonatology) in the Oregon Health & Science University School of Medicine and OHSU Doernbecher Children’s Hospital. “Reducing virulence factors in newborns has the potential for lifelong health benefits to this particularly vulnerable population — it’s tantamount to starting life out on the right foot.”
By Kristin Lawless, New York Times Correspondent | June 17, 2018
We may be missing the key to one of the biggest boons to public health since the introduction of iodine into the food supply in 1924.
Scientists at the University of California, Davis, have found that a strain of bacteria called B. infantis that is thought to have been the dominant bacterium in the infant gut for all of human history is disappearing from the Western world. According to their research, this was probably caused by the rise in cesarean births, the overuse of antibiotics and the use of infant formula in place of breast milk.
Indeed, nine out of 10 American babies don’t harbor this bacterium in their gut, while researchers suspect that the majority of infants in less industrialized countries do...Read more on NYtimes.com
Davis, California, June 13, 2018 – Evolve BioSystems, Inc., the leading infant gut microbiome company, today announced that it has completed a $40 million Series C round of funding co-led by the Bill & Melinda Gates Foundation, and Horizons Ventures, the venture division of the Li Ka Shing Foundation.
12/6/2017 — The bacteria in Evivo, Bifidobacterium longum subsp. infantis (B. infantis) is the critically important bacteria in baby’s gut microbiome early in life. It helps to program metabolism and the immune system and supports the complete digestion of nutrients.
Unfortunately, due to generations of modern medical practices such as antibiotics and C-sections, most babies no longer acquire B. infantis early in life. Without it, potentially harmful bacteria thrive which have been linked to higher risk of colic, eczema, allergies, diabetes, and obesity. To date, probiotics have focused on general gut health and digestion, but until now had not demonstrated the ability to reduce potentially harmful bacteria.
In a controlled clinical trial led by University of California, Davis Medical Center, breastfed babies were given Evivo (activated B. infantis EVC001) once a day and compared to a similar group of babies who did not receive Evivo. This study showed the first-ever restoration of the baby gut microbiome via Evivo. Babies given Evivo saw a 79% increase in bifidobacteria. These Evivo babies also experienced an unprecedented 80% reduction of groups of potentially harmful bacteria such as E. coli, clostridia, Staphylococcus (Staph), and Streptococcus (Strep), which have been linked to disease later in life. Finally, across all babies in the study, those high in bifidobacteria had four times lower levels of endotoxin, a compound known to cause inflammation.
In summary, providing Evivo to babies in this clinical study completely restored the naturally protective gut microbiome in 100% of breastfed babies and significantly reduced potentially harmful groups of bacteria compared to babies who didn’t receive Evivo.
These data have been presented at major international medical and scientific conferences, and have been published in peer-reviewed journals. Key presentations include:
“The Infant Microbiota and Probiotic Intake (IMPRINT) Study: Safety and Tolerability of Consuming Bifidobacterium longum subspecies infantis in Exclusively Breastfed Term Infants”.
Pediatric Academic Society (PAS) 2017
Evivo is the only infant probiotic to substantially and persistently transform the infant gut microbiome
Evivo with MCT Oil is easy to administer. Evivo with MCT Oil is easy to administer. View feeding directions.
Intrapartum antibiotics for GBS prophylaxis alter colonization patterns in the early infant gut microbiome of low risk infants
Mucus Degradation and Gut Microbes: Maintaining Gut Barrier Function in the Preterm Infant
B.infantis Colonization Creates A Protective Environment In The Infant Gut
Probiotics for Hospital Use: Choosing the Right Strain, Right Food and Right Form
Evivo™ was safely consumed and well-tolerated in a controlled clinical trial.
Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut
Breast milk feeds helpful microbes, fights harmful ones, provides immunity, and jump-starts a newborn’s life
97% of babies no longer acquire B.infantis, allowing for potentially harmful bacteria to dominate the gut. Learn more.
Elevated Fecal pH Indicates a Profound Change in the Breastfed Infant Gut Microbiome Due to Reduction of Bifidobacterium over the Past Century
One vital beneficial bacteria is designed by nature to live in babies’ gut, and thrive in the presence of human breast milk: Bifidobacterium (including B. infantis). In fact, the higher the levels of Bifidobacterium in baby’s gut early in life reduces the amount of potentially harmful bacteria which are linked later in life to a higher risk of many conditions like colic, eczema, allergies, diabetes, and obesity. In this recent clinical trial led by The University of California, breast fed babies were given Evivo (activated B. infantis) once a day for a month and were compared to breast fed babies who didn’t receive any probiotic. After a month, Evivo babies had significantly higher levels of total Bifidobacterium in their gut compared to babies who didn’t receive Evivo. This once-daily probiotic is clinically proven to restore Bifidobacterium to baby’s gut and reduce the amount of potentially harmful bacteria. It’s the first and only baby probiotic of its kind to help establish the foundation of lifelong well-being.
Get the latest updates.
More Media Coverage...
Human Milk Oligosaccharides (HMOs) are special carbohydrates that are food for baby’s gut bacteria. One key beneficial bacteria, B. infantis, is unique and able to capture all these carbohydrates that might otherwise be wasted, consuming them fully allowing B. infantis to grow and protect baby’s gut, and convert them into essential nutrients that are critical for baby’s developing metabolism and immune system.
Probiotics are ‘good’ bacteria that help keep your gut microbiome healthy. Historically, probiotics have been taken with the hope to relieve symptoms such as gas, bloating, or other digestive issues. However, new research has found that gut health is connected to other conditions such as colic, eczema, allergies, diabetes, and obesity and may have a much larger impact on overall health, beyond only symptomatic relief.
Prebiotics are carbohydrates that cannot be digested by the human body. Instead, they are ‘food’ for the gut microbiome. For babies, the most important prebiotics are found in breast milk and are called Human Milk Oligosaccharides (HMOs). HMOs are the third most abundant nutrient in breast milk and are critical to ‘feed’ good bacteria in baby’s gut.
A gut microbiome is a collection of trillions of microorganisms, or bacteria, that live in our intestines, or gut.
By nature’s design, beneficial and protective bacteria are passed from mom to baby during the birthing process, creating baby’s unique gut microbiome. However, the unintended consequences of modern medical practices such as antibiotics, c-sections, and formula feeding have led to a decrease in this mom to baby transfer.
In collaboration with the University of California Medical Center, we completed a clinical trial in which breast fed babies were given Evivo once a day for a month and were compared to breast fed babies who didn’t receive any probiotic. After a month, Evivo babies had significantly higher levels of the key good bacteria, B. infantis, in their gut compared to babies who didn’t receive any Evivo. This good bacteria is critical for proper immune system and metabolic development during the first six months of life.